Haldol: Advanced Antipsychotic Control for Severe Mental Disorders
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $5.37 | $161.03 (0%) | 🛒 Add to cart |
| 60 | $4.37 | $322.06 $262.05 (19%) | 🛒 Add to cart |
| 90 | $4.03 | $483.10 $363.07 (25%) | 🛒 Add to cart |
| 120 | $3.87 | $644.13 $464.09 (28%) | 🛒 Add to cart |
| 180 | $3.70 | $966.19 $666.13 (31%) | 🛒 Add to cart |
| 270 | $3.59 | $1449.29 $969.19 (33%) | 🛒 Add to cart |
| 360 | $3.53
Best per pill | $1932.38 $1272.25 (34%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.78 | $167.03 (0%) | 🛒 Add to cart |
| 90 | $2.42 | $250.55 $218.04 (13%) | 🛒 Add to cart |
| 120 | $2.23 | $334.07 $268.05 (20%) | 🛒 Add to cart |
| 180 | $2.05 | $501.10 $369.07 (26%) | 🛒 Add to cart |
| 270 | $1.93 | $751.65 $520.10 (31%) | 🛒 Add to cart |
| 360 | $1.86
Best per pill | $1002.20 $671.13 (33%) | 🛒 Add to cart |
Synonyms
| |||
Haldol (haloperidol) is a first-generation (typical) antipsychotic medication belonging to the butyrophenone class, developed for the management of severe psychiatric conditions. It functions primarily as a potent dopamine D2 receptor antagonist, effectively modulating dopaminergic pathways implicated in psychosis, agitation, and certain behavioral disorders. With a well-established efficacy profile spanning decades of clinical use, Haldol remains a cornerstone in acute and maintenance treatment protocols for schizophrenia, Tourette’s syndrome, and severe behavioral disturbances. Its injectable decanoate formulation offers prolonged symptom control, enhancing adherence and stability in long-term management. This agent is recognized for its reliability in emergency settings and structured therapeutic regimens under specialist supervision.
Features
- Active ingredient: Haloperidol
- Available forms: Oral tablets, oral concentrate, short-acting intramuscular injection, long-acting decanoate injection (Haldol Decanoate)
- Standard strengths: Tablets: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg; Injection: 5 mg/mL; Decanoate: 50 mg/mL, 100 mg/mL
- Half-life: Approximately 12–36 hours (oral); Decanoate: ~3 weeks
- Metabolism: Hepatic, primarily via CYP3A4
- Excretion: Renal and fecal
Benefits
- Provides rapid control of acute psychotic symptoms and agitation, often within hours when administered parenterally.
- Effective long-term management of chronic psychotic disorders, reducing relapse frequency and hospitalization.
- Available in a decanoate formulation for sustained release, ensuring consistent plasma levels and improved compliance.
- Demonstrates efficacy in treatment-resistant cases and severe behavioral syndromes where other agents may fail.
- Well-established safety and monitoring protocols, with extensive clinical experience guiding use.
- Cost-effective option within antipsychotic formularies, providing reliable symptom control.
Common use
Haldol is indicated for the management of manifestations of psychotic disorders, including schizophrenia. It is also used in the control of tics and vocal utterances of Tourette’s syndrome in children and adults. Additionally, it is prescribed for severe behavioral problems in children characterized by combativeness and explosive hyperexcitable behavior. Short-acting injectable forms are utilized in emergency settings for rapid tranquilization of acutely agitated patients. Off-label uses may include management of delirium, agitation in dementia (with extreme caution), and as an antiemetic in specific scenarios.
Dosage and direction
Dosage must be individualized based on severity of symptoms, patient response, and tolerability. For psychosis in adults: initial oral dose is 0.5–5 mg 2–3 times daily; maintenance dose is often 1–15 mg/day. For IM administration: 2–5 mg, repeat every 4–8 hours as needed. Haldol Decanoate: initial dose is 10–15 times the previous daily oral dose, IM every 4 weeks; maximum 100 mg initially. For Tourette’s: initial dose 0.5–1.5 mg orally 2–3 times daily. Always titrate gradually; use the lowest effective dose. Administer with or without food.
Precautions
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Haldol is not approved for the treatment of patients with dementia-related psychosis. Use with caution in patients with cardiovascular disorders, history of seizures, Parkinson’s disease, or hepatic impairment. May cause drowsiness; advise against operating machinery until response is known. Regular monitoring of electrolyte levels, liver function, and complete blood count is recommended during prolonged therapy. Neurological monitoring for extrapyramidal symptoms is essential.
Contraindications
Haldol is contraindicated in patients with severe toxic central nervous system depression or comatose states from any cause. Hypersensitivity to haloperidol or any component of the formulation. Patients with Parkinson’s disease or dementia with Lewy bodies due to high sensitivity to extrapyramidal effects. Avoid in cases of known QT prolongation or significant cardiac arrhythmias. Not recommended during pregnancy unless potential benefit justifies potential risk to the fetus.
Possible side effect
Common: Extrapyramidal symptoms (dystonia, akathisia, parkinsonism), sedation, dizziness, dry mouth, constipation, blurred vision. Serious: Neuroleptic malignant syndrome (NMS), tardive dyskinesia, QT prolongation, seizures, orthostatic hypotension, leukopenia, agranulocytosis. Hyperprolactinemia may occur, leading to galactorrhea, amenorrhea, gynecomastia. Skin reactions including photosensitivity. Injection site reactions with IM formulations.
Drug interaction
May enhance CNS depression with alcohol, benzodiazepines, opioids. CYP3A4 inhibitors (e.g., ketoconazole) can increase haloperidol levels. CYP3A4 inducers (e.g., carbamazepine) may decrease efficacy. Concurrent use with other QT-prolonging agents (e.g., antiarrhythmics, certain antibiotics) increases arrhythmia risk. Lithium may increase neurotoxicity risk. Anticholinergic agents may exacerbate certain side effects. Caution with antihypertensives due to additive hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for the missed one. For once-daily regimens, if missed, take within 12 hours; otherwise, skip. For multiple daily doses, resume regular schedule. Contact healthcare provider for guidance if multiple doses are missed, as retitration may be necessary.
Overdose
Symptoms may include severe extrapyramidal reactions, hypotension, sedation, coma, respiratory depression, and QT prolongation. Management is supportive and symptomatic: ensure airway patency, administer activated charcoal if recent ingestion, monitor ECG for arrhythmias. Consider benzodiazepines for agitation; avoid epinephrine in hypotension. Specific antidote not available. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature (15–30°C or 59–86°F). Protect from light and moisture. Keep oral concentrate in original container; do not freeze. Keep all medications out of reach of children and pets. Do not use if discolored or containing particulate matter. For decanoate injection, store upright; allow to reach room temperature and shake well before administration.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations. Do not initiate, discontinue, or change dosage without medical supervision. The manufacturer and publisher are not liable for any outcome resulting from the use or misuse of this information.
Reviews
“Haldol has been instrumental in managing treatment-resistant schizophrenia in our inpatient unit. The decanoate formulation particularly improves long-term outcomes.” – Psychiatrist, 15 years experience
“Effective for acute agitation, though extrapyramidal side effects require vigilant management. A reliable agent in emergency psychiatry.” – ER Physician
“While newer atypicals are often first-line, Haldol remains valuable for certain cases, especially when cost and potency are considerations.” – Clinical Pharmacist
“Patient response varies; some achieve remarkable stability, others struggle with side effects. Individualized dosing is key.” – Psychiatric Nurse Practitioner
“Using Haldol decanoate has significantly reduced relapse rates in my practice, but requires careful injection technique and monitoring.” – Community Mental Health Specialist